RBC Capital analyst Douglas Miehm reiterated an Sector Perform rating and $33 price target on Valeant Pharmaceuticals (NYSE: VRX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE